LUMOS
Trial status: CompletedProtocol title
Purpose of the study
This Phase II pilot umbrella study will match tumours in recurrent lower grade glioma patients on a molecular level with the best treatments. We will assist in accessing these drugs, including creating trials of new treatments. Lastly, we will collect an invaluable set of tissue and blood before and after treatment for future research into better treatments.
Intervention
Single molecularly-guided arm: Patients undergo molecular profiling of contemporaneous tumour tissue. If an actionable mutation is identified, a Molecular Tumour Advisory Panel recommends a matched targeted therapy. In this pilot, two participants received targeted therapies through compassionate access.
Comparator arm: Patients without actionable targets—or when matched drugs were inaccessible—received standard-of-care chemotherapy, determined with their treating clinician
Study Chair
Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown
NSW, 1450
Australia
Email: lumos.study@sydney.edu.au
Design
Phase II, multi-centre, randomised, blinded, parallel arms
Cancer Type
Publications
- LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. https://doi.org/10.1136/bmjopen-2021-054075
- INNV-08. LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY, https://doi.org/10.1093/neuonc/noab196.420